Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.

Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, FitzGerald O, Poole AR, Bresnihan B, Veale DJ, Fearon U.

Arthritis Rheum. 2012 Apr;64(4):1035-45. doi: 10.1002/art.33455.

3.

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.

Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK.

Rheumatology (Oxford). 2002 May;41(5):484-9.

4.

Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.

Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, Bresnihan B, Veale DJ, Fearon U.

Arthritis Res Ther. 2009;11(4):R113. doi: 10.1186/ar2772.

5.

Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade.

Rooney T, Roux-Lombard P, Veale DJ, FitzGerald O, Dayer JM, Bresnihan B.

Ann Rheum Dis. 2010 Apr;69(4):706-14. doi: 10.1136/ard.2009.108324.

PMID:
19460761
7.

Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.

Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ.

Arthritis Rheum. 2003 Nov;48(11):3085-95.

8.

Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.

Goldbach-Mansky R, Lee JM, Hoxworth JM, Smith D 2nd, Duray P, Schumacher RH Jr, Yarboro CH, Klippel J, Kleiner D, El-Gabalawy HS.

Arthritis Res. 2000;2(2):145-53.

9.

Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model.

Connolly M, Marrelli A, Blades M, McCormick J, Maderna P, Godson C, Mullan R, FitzGerald O, Bresnihan B, Pitzalis C, Veale DJ, Fearon U.

J Immunol. 2010 Jun 1;184(11):6427-37. doi: 10.4049/jimmunol.0902941.

10.

E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.

Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU.

J Rheumatol. 2009 Jul;36(7):1371-9. doi: 10.3899/jrheum.080755. Erratum in: J Rheumatol. 2011 Jan;38(1):183.

PMID:
19487269
12.
13.

A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A.

Mullan RH, McCormick J, Connolly M, Bresnihan B, Veale DJ, Fearon U.

Am J Pathol. 2010 Apr;176(4):1999-2008. doi: 10.2353/ajpath.2010.090014.

15.

Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10.

Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, Breedveld FC, Huizinga TW.

Ann Rheum Dis. 2002 Nov;61(11):975-80.

16.

Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts.

Lee A, Qiao Y, Grigoriev G, Chen J, Park-Min KH, Park SH, Ivashkiv LB, Kalliolias GD.

Arthritis Rheum. 2013 Apr;65(4):928-38. doi: 10.1002/art.37853.

17.

The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue.

Abreu JR, de Launay D, Sanders ME, Grabiec AM, van de Sande MG, Tak PP, Reedquist KA.

Arthritis Res Ther. 2009;11(4):R121. doi: 10.1186/ar2785.

19.

The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.

Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP.

Arthritis Rheum. 2000 Feb;43(2):270-4.

20.

Piascledine modulates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis synoviocytes.

Cinelli M, Guiducci S, Del Rosso A, Pignone A, Del Rosso M, Fibbi G, Serratì S, Gabrielli A, Giacomelli R, Piccardi N, Matucci Cerinic M.

Scand J Rheumatol. 2006 Sep-Oct;35(5):346-50.

PMID:
17062432
Items per page

Supplemental Content

Support Center